As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: January 22, 2014
by Emily Mullin for Fierce Biotech Research:
For the first time, researchers at the Cleveland Clinic have linked a protein in the brain to critical memory loss associated with amyloid beta in Alzheimer’s patients.
The culprit is neuroligin-1 (NLGN1), which is known to be involved in memory formation. In a new study that appears in Nature Neuroscience, investigators have now linked the protein to amyloid-associated memory loss.
Alzheimer’s disease is characterized by the buildup of amyloid beta plaques in the brain. But it’s still unknown whether these amyloid plaques cause Alzheimer’s or if they’re a byproduct of the disease. Drug research that has used the amyloid theory as a basis for new Alzheimer’s therapies has been riddled with clinical failures.
The accumulation of these amyloid beta proteins induces inflammation in the brain. This inflammation causes certain gene modifications that interrupt the functioning of synapses in the brain, leading to memory loss.
In animal models, Cleveland Clinic researchers found that during this neuroinflammatory process, NLGN1 disrupts the synaptic network in the brain responsible for developing and maintaining memories. Destroying these vital brain connections can cause the type of memory loss seen in Alzheimer’s disease. The finding could provide scientists with a new approach for preventing and treating the devastating and irreversible disease.
Previous research by the Cleveland Clinic team found that a novel compound called MDA7 can potentially stop the neuroinflammatory process that leads to the modification of NLGN1. In an animal model, the compound restored cognition, memory and synaptic plasticity–an important foundation of learning and memory.
Researchers have already completed in vitro studies and preliminary clinical toxicology and pharmacokinetic work and plan to begin a Phase I human study on the safety of this class of compounds in the near future.
A recent meta-analysis investigates whether sex, age, and a particular genotype are associated with a greater risk of developing Alzheimer’s disease. Alzheimer’s Disease (AD) is a chronic neurodegenerative condition, characterized by cognitive deficits in memory, thinking,...
Just because someone has difficulty remembering things, it doesn’t necessarily mean that what they’re experiencing is a symptom of dementia, a new Canadian study says. But if the person is not aware of the...
In the late 1980s, psychologist James Pennebaker developed a form of writing therapy called expressive writing. When you engage in expressive writing, you write about your deepest thoughts and feelings without concern for...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.